OTLK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Outlook Therapeutics Inc (OTLK) is not a good buy for a beginner investor with a long-term strategy at this time. The company is facing significant challenges, including FDA setbacks, poor financial performance, and neutral trading sentiment. While there are some positive developments in Europe, they do not outweigh the risks associated with the stock.
The technical indicators are mixed. The MACD is positive and expanding, suggesting some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. The stock is trading near its pivot level (0.431), with resistance at 0.472 and support at 0.39.
Marketing authorization for LYTENAVA™ in the EU and UK, with plans for further European expansion.
Safety profile of ONS-5010 is favorable, with no safety concerns raised by the FDA.
FDA issued a Complete Response Letter for ONS-5010, citing insufficient evidence of effectiveness.
Analysts have downgraded price targets and expressed concerns about the company's commercial viability and path forward.
Financial performance is poor, with significant net income and EPS declines.
In 2025/Q4, the company reported no revenue growth (0% YoY), a net income drop of -333.56% YoY, and an EPS decline of -216.67% YoY. Gross margin increased slightly to 4.05%. Overall, the financials are weak and do not support a strong investment case.
Analysts have downgraded price targets significantly, with H.C. Wainwright lowering the target to $0.50 and Chardan lowering it to $1. Both maintain Neutral ratings, citing concerns over the company's ability to secure FDA approval and commercialize its products effectively.
